Last reviewed · How we verify
intravenous injection of labeled cRBC
intravenous injection of labeled cRBC is a Biologic drug developed by Etablissement Français du Sang. It is currently in Phase 1 development.
At a glance
| Generic name | intravenous injection of labeled cRBC |
|---|---|
| Sponsor | Etablissement Français du Sang |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intravenous injection of labeled cRBC CI brief — competitive landscape report
- intravenous injection of labeled cRBC updates RSS · CI watch RSS
- Etablissement Français du Sang portfolio CI
Frequently asked questions about intravenous injection of labeled cRBC
What is intravenous injection of labeled cRBC?
intravenous injection of labeled cRBC is a Biologic drug developed by Etablissement Français du Sang.
Who makes intravenous injection of labeled cRBC?
intravenous injection of labeled cRBC is developed by Etablissement Français du Sang (see full Etablissement Français du Sang pipeline at /company/etablissement-fran-ais-du-sang).
What development phase is intravenous injection of labeled cRBC in?
intravenous injection of labeled cRBC is in Phase 1.